🔥🐔 BizChicken 🐔🔥

Companies Similar to TScan Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Anixa Biosciences, Inc.

Anixa Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

Chimeric Endocrine Receptor T-cell Technology, Anti-Viral Drug Candidates, Vaccines

Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines for oncology and infectious diseases, including novel CAR-T technologies for ovarian cancer and vaccines for breast and ovarian cancer.

Tags: CAR-T therapy, COVID-19, anti-viral drugs, biotechnology, infectious diseases, oncology, vaccine development

Symbol: ANIX

Recent Price: $2.50

Industry: Biotechnology

CEO: Dr. Amit Kumar Ph.D.

Sector: Healthcare

Employees: 4

Address: 3150 Almaden Expressway, San Jose, CA 95118

Phone: 408 708 9808

Last updated: 2024-12-31

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock logo
Market Cap: Medium
Employees: Low

CRG-022

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.

Tags: B-cell Malignancies, Biotechnology, CAR T-cell Therapies, Cancer Treatment, Clinical-stage

Symbol: CRGX

Recent Price: $13.76

Industry: Biotechnology

CEO: Ms. Gina Chapman

Sector: Healthcare

Employees: 150

Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403

Phone: 650-379-6143

Leadership

  • Gina Chapman, President and Chief Executive Officer
  • Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
  • Ginna Laport, MD, Chief Medical Officer
  • Shishir Gadam, PhD, Chief Technical Officer
  • Michael Ports, PhD, Chief Scientific Officer
  • Kari Leetch, Chief People Officer
  • Halley Gilbert, JD, Chief Legal Officer
  • Bethany Rogers, SVP, Product Strategy and Commercialization
  • Faisal Shawwa, SVP, Finance
  • Tonia J. Buchholz, PhD, Head of Clinical Science
  • Kanika Chawla, PhD, Head of Process Sciences
  • Sandra Chen, Head of Clinical Quality and Risk Management
  • Michelle Gray, Head of Clinical Operations
  • Adam Haskett, Head of External Manufacturing
  • David Hoffman, JD, Head of Intellectual Property & Transactions
  • Anissa Irwin, Head of Quality Assurance and Systems
  • Brett Masterson, Head of Marketing
  • Rob McCombie, Head of CMC Regulatory
  • Frank McDonald, Head of Clinical Data Management
  • Priya Parameswaran, Head of Corporate Strategy and Business Operations
  • Shabnum Patel, PHD, Head of MSAT
  • Mary Rodley, Head of CMC Strategy and Operations
  • Abhijeet Sarvaiya, Head of Statistical Programming
  • Brian Schoelkopf, Head of FP&A
  • Christophe Suchet, Head of IT
  • Beth Vasievich, PhD, Head of Commercial Planning and Operations
  • Jun Wang, Head of Procurement
  • John Orwin, Chairman of the Board
  • Abraham Bassan, Board Director
  • Kapil Dhingra, M.B.B.S, Board Director
  • Reid Huber, PHD, Board Director
  • David Lubner, Board Director
  • Krishnan Viswanadhan, Pharm.D, Board Director
  • Jane Pritchett Henderson, Board Director

Last updated: 2024-12-31

Gain Therapeutics, Inc.

Gain Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Site-Directed Enzyme Enhancement Therapy platform

Gain Therapeutics, Inc. is a biotechnology company developing therapies for diseases caused by protein misfolding, focusing on rare genetic diseases and neurological disorders. It utilizes its proprietary technology to discover and develop molecules targeting misfolded proteins.

Tags: allosteric regulation, biotechnology, neurological disorders, protein misfolding, rare genetic diseases

Symbol: GANX

Recent Price: $2.18

Industry: Biotechnology

CEO: Mr. Gene Mack M.B.A.

Sector: Healthcare

Employees: 29

Address: 4800 Montgomery Lane, Bethesda, MD 20814

Phone: 301 500 1556

Last updated: 2024-12-31

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

Engineered T Cell Therapeutics

CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment, particularly targeting hematologic malignancies using innovative immune system integration strategies.

Tags: T cell therapeutics, biotechnology, cancer treatment, hematologic malignancies, immunotherapy

Symbol: CERO

Recent Price: $0.06

Industry: Biotechnology

CEO: Mr. Christopher B. Ehrlich M.B.A.

Sector: Healthcare

Employees: 8

Address: 201 Haskins Way, South San Francisco, CA 94080

Phone: 650-407-2376

Last updated: 2024-12-31

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. logo
Market Cap: Medium
Employees: Lowest

TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, TSHA-101

Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies for treating monogenic diseases of the central nervous system, with a pipeline including treatments for conditions such as giant axonal neuropathy, Rett syndrome, and GM2 gangliosidosis.

Tags: CNS, biotechnology, gene therapy, healthcare, monogenic diseases

Symbol: TSHA

Recent Price: $1.73

Industry: Biotechnology

CEO: Mr. Sean P. Nolan

Sector: Healthcare

Employees: 52

Address: 3000 Pegasus Park Drive, Dallas, TX 75247

Phone: 214 612 0000

Last updated: 2024-12-31

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

UCART19

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

Tags: CAR T cell, allogeneic T cell therapies, cancer treatment, clinical trials, immuno-oncology

Symbol: ALLO

Recent Price: $2.10

Industry: Biotechnology

CEO: Dr. David D. Chang M.D., Ph.D.

Sector: Healthcare

Employees: 232

Address: 210 East Grand Avenue, South San Francisco, CA 94080

Phone: 650 457 2700

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

Beam Therapeutics Inc.

Beam Therapeutics Inc. logo
Market Cap: High
Employees: Medium

precision genetic medicines

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.

Tags: Glycogen Storage Disease Type Ia, beta thalassemia, biotechnology, collaboration, genetic medicine, sickle cell disease

Symbol: BEAM

Recent Price: $25.28

Industry: Biotechnology

CEO: Mr. John M. Evans M.B.A.

Sector: Healthcare

Employees: 472

Address: 238 Main Street, Cambridge, MA 02142

Phone: 857 327 8775

Last updated: 2024-12-31

Cogent Biosciences, Inc.

Cogent Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

CGT9486

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.

Tags: biotechnology, genetically defined diseases, precision therapies, tyrosine kinase inhibitor

Symbol: COGT

Recent Price: $7.67

Industry: Biotechnology

CEO: Mr. Andrew R. Robbins M.B.A.

Sector: Healthcare

Employees: 164

Address: 200 Cambridge Park Drive, Cambridge, MA 02140

Phone: 617 945 5576

Last updated: 2024-12-31

Design Therapeutics, Inc.

Design Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

Gene TAC

Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing therapies for genetic diseases caused by nucleotide repeat expansions. Their portfolio includes products targeting Friedreich Ataxia and Myotonic Dystrophy Type-1, as well as Gene TAC candidates for other similar diseases.

Tags: Friedreich Ataxia, Gene TAC, Myotonic Dystrophy Type-1, biopharmaceutical, genetic diseases, nucleotide repeat expansions, preclinical-stage, therapy development

Symbol: DSGN

Recent Price: $6.17

Industry: Biotechnology

CEO: Mr. Pratik Shah Ph.D.

Sector: Healthcare

Employees: 57

Address: 6005 Hidden Valley Road, Carlsbad, CA 92011

Phone: 858 293 4900

Last updated: 2024-12-31

Janux Therapeutics, Inc.

Janux Therapeutics, Inc. logo
Market Cap: High
Employees: Low

Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr)

Janux Therapeutics is a biopharmaceutical company developing cancer therapeutics leveraging their proprietary TRACTr and TRACIr platform technologies, targeting specific antigens and improving T cell anti-tumor activity.

Tags: T cells, TRACIr, TRACTr, biopharmaceutical, cancer therapeutics, immunotherapy

Symbol: JANX

Recent Price: $52.50

Industry: Biotechnology

CEO: Dr. David Alan Campbell Ph.D.

Sector: Healthcare

Employees: 64

Address: 11099 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858 750 4700

Last updated: 2024-12-31

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TTX-MC138

Trans Code Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs and diagnostics for treating metastatic disease. Their lead product, TTX-MC138, is aimed at metastatic cancer treatment, along with a range of other therapeutic platforms targeting cancer through innovative RNA- and CRISPR-based technologies.

Tags: CRISPR technology, RNA-based therapy, biopharmaceutical, cancer treatment, metastatic disease

Symbol: RNAZ

Recent Price: $3.76

Industry: Biotechnology

CEO: Mr. Thomas A. Fitzgerald M.B.A.

Sector: Healthcare

Employees: 10

Address: 6 Liberty Square, Boston, MA 02109

Phone: 857-837-3099

Last updated: 2024-12-31

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

therapeutics for cancer

TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.

Tags: TJ004309, TRC102, YH001, biopharmaceutical, cancer therapeutics, clinical trials, envafolimab

Symbol: TCON

Recent Price: $0.03

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 17

Address: 4350 La Jolla Village Drive, San Diego, CA 92122

Phone: 858 550 0780

Last updated: 2024-12-31

TScan Therapeutics, Inc.

TScan Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

T cell receptor-engineered T cell therapies

TScan Therapeutics, Inc. is a preclinical-stage biopharmaceutical company that develops T cell receptor-engineered T cell therapies for cancer treatment. It is working on therapies for hematologic malignancies and solid tumors, as well as vaccines for infectious diseases like SARS-CoV-2.

Tags: Novartis collaboration, SARS-CoV-2, T cell therapies, biopharmaceutical, cancer treatment, hematologic malignancies, infectious diseases, solid tumors

Symbol: TCRX

Recent Price: $3.00

Industry: Biotechnology

CEO: Dr. Gavin MacBeath Ph.D.

Sector: Healthcare

Employees: 175

Address: 830 Winter Street, Waltham, MA 02451

Phone: 857 399 9500

Leadership

  • Stephen Biggar, M.D., Ph.D., Partner at Baker Bros. Advisors LP
  • Katina Dorton, J.D., M.B.A., CFO of Nodthera
  • Gabriela Gruia, M.D., Chief Development Officer at Ichnos Sciences
  • Barbara Klencke, M.D., Former Chief Medical Officer and Chief Development Officer of Sierra Oncology Inc.
  • Gavin MacBeath, Ph.D., CEO of TSCAN
  • Garry Nicholson, Former President of Pfizer Oncology
  • R. Keith Woods, Former Chief Operating Officer of argenx

Last updated: 2024-12-31

TG Therapeutics, Inc.

TG Therapeutics, Inc. logo
Market Cap: High
Employees: Low

Ublituximab, Umbralisib, Cosibelimab, TG-1701, TG-1801

TG Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.

Tags: B-cell malignancies, BTK inhibitor, Cosibelimab, Ublituximab, Umbralisib, autoimmune diseases, biopharmaceutical

Symbol: TGTX

Recent Price: $31.45

Industry: Biotechnology

CEO: Mr. Michael S. Weiss Esq.

Sector: Healthcare

Employees: 264

Address: 2 Gansevoort Street, New York, NY 10014

Phone: 212 554 4484

Leadership

  • Michael S. Weiss, Chairman, President, and Chief Executive Officer
  • Sean A. Power, CPA, Chief Financial Officer
  • Adam Waldman, Chief Commercialization Officer

Last updated: 2024-12-31

Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TPST-1495, TPST-1120, TREX-1

Tempest Therapeutics Inc. is a clinical-stage oncology company developing small molecule therapeutics to treat cancer, with key programs in TPST-1495 and TPST-1120, and research in TREX-1 enzyme modulation.

Tags: biotechnology, cancer treatment, clinical-stage, drug development, immune response, oncology, small molecule therapeutics

Symbol: TPST

Recent Price: $0.84

Industry: Biotechnology

CEO: Mr. Stephen R. Brady J.D., LLM

Sector: Healthcare

Employees: 17

Address: 7000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 798 8589

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Marker Therapeutics, Inc.

Marker Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Multi TAA-specific T cell technology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing T cell-based immunotherapies and peptide-based vaccines for treating hematological malignancies and solid tumors in the US.

Tags: T cell therapy, cancer treatment, hematological malignancies, immuno-oncology, solid tumors, vaccines

Symbol: MRKR

Recent Price: $3.34

Industry: Biotechnology

CEO: Dr. Juan F. Vera M.D.

Sector: Healthcare

Employees: 8

Address: 3200 Southwest Freeway, Houston, TX 77027

Phone: 713 400 6400

Leadership

  • David Eansor, President, Protein Sciences Segment, Bio-Techne Corporation
  • Steve Elms, Managing Partner, Aisling Capital
  • John R. Wilson, CEO, Wilson Wolf Manufacturing, Co-Founder Marker Therapeutics, Co-Founder AlloVir
  • Juan F. Vera, Chief Executive Officer & Co-Founder, Marker Therapeutics, Co-Founder, AlloVir
  • Katharine Knobil, M.D., Chief Medical Officer at Agilent Technologies, Inc.

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31